Thematic photoMartin FalbisonerCC BY-SA 3.0Resized, encoded as WebP; displayed with responsive cropping under the original licenceSEC EDGAR published this disclosure on 2026-07-17. Read the original document for its full text and supporting detail.
Open the original document at SEC EDGAR ↗accession0001221590-26-000023
acquired disposedA
codeP
direct or indirectD
form4
is derivativefalse
issuer nameKeros Therapeutics, Inc.
labelOpen market purchase
Source record & verificationDates, provenance and technical details
Context
links are based on the recorded entity typeRecorded payloadStructured source data
Recorded payload
JSON payload as stored after parsing{
"accession": "0001221590-26-000023",
"acquired_disposed": "A",
"code": "P",
"direct_or_indirect": "D",
"form": "4",
"is_derivative": false,
"issuer_name": "Keros Therapeutics, Inc.",
"label": "Open market purchase",
"person_name": "BIENAIME JEAN JACQUES",
"price": 10.61,
"role": "Director",
"security": "Common Stock",
"shares": 1000,
"shares_owned_after": 18592,
"source_path": "edgar/data/1221590/0001221590-26-000023.txt",
"ticker": "KROS",
"value": 10610
}Evidence-based analysis
facts, provenance and explicit model coverageDescriptive evidence from the stored source record; it is not advice, a forecast or a legal conclusion.